David Henry MD
Clinical Professor of Medicine, Pennsylvania Hospital, Philadelphia, PennsylvaniaIn addition to his clinical responsibilities, Dr. Henry is a member of the American Board of Internal Medicine’s Subspecialty SEP Board of Hematology and a principal investigator for the Eastern Cooperative Oncology Group, Accelerated Community Oncology Research Network, and International Oncology Network research groups. He is also principal investigator for several HIV oncology and cytokine studies with white blood cell and red blood cell growth factors. Dr. Henry’s main interests for publication and research are anemia and neutropenia in oncology. He is the Editor-in-Chief of MDEDGE.com/hematology-oncology and a reviewer for The New England Journal of Medicine, Journal of Clinical Oncology, Archives of Internal Medicine, and The Oncologist. He is also the author of a weekly podcast titled Blood and Cancer on iTunes.
Dr. Henry is a past winner of the annual Blockley-Osler Award for teaching at the University of Pennsylvania School of Medicine, and is the director of the University of Vienna medical student exchange program in Philadelphia. He also has appeared 3 times in Philadelphia magazine’s Top Doctors feature.
Positions:
Clinical Professor of Medicine, Pennsylvania Hospital, Philadelphia, PA
Member, Joan Karnell Cancer Center at Pennsylvania Hospital
Community oncologist
Degree:
University of Pennsylvania School of Medicine, MD
Postgraduate Training:
Resident, University of Pennsylvania School of Medicine
Fellow, University of Pennsylvania School of Medicine
Board Certification:
Medical oncology
Hematology
Clinical Interests:
Anemia, neutropenia, thrombocytopenia, and bone metastases
Recent Contributions to PracticeUpdate:
- CNS Efficacy of Osimertinib With or Without Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC
- 2023 Top Story in Oncology: Circulating Tumor DNA Analysis to Guide Adjuvant Therapy
- ESMO 2023: Recommendations From Dr. David Henry for General Oncology
- Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma
- Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery in ER-Positive and HER2-Negative Breast Cancer
- Neoadjuvant Chemoradiation for Treatment of LARC
- Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC
- ASCO 2023: Abstract Recommendations From Dr. David Henry
- 2022 Top Story in Oncology: Durvalumab Plus Gemcitabine and Cisplatin as First-Line Treatment for Advanced Biliary Tract Cancer
- ESMO 2022: Recommendations From Dr. David Henry for General Oncology